Clearance Summary
Adaptive Biotechnologies clonoSEQ Assay received FDA 510(k) clearance under submission number K200009, sponsored by Adaptive Biotechnologies Corporation. The device was reviewed via the Traditional premarket notification pathway and assigned to the Pathology review panel. The statutory decision date of record is 2020-08-05.
- Submission: K200009
- Applicant / Sponsor: Adaptive Biotechnologies Corporation
- Clearance pathway: Traditional
- Review panel: Pathology
- Device class: Class II
- Regulation citation: 21 CFR 866.6100
- Decision date: 2020-08-05
Classification & Regulation
This clearance is catalogued under FDA product code QDC and 21 CFR 866.6100, within the Pathology review panel as a Class II device.